- ISIN
- US92189F7261
- CUSIP
- 92189F726
- Issuer
- VanEck
- Inception Date
- Dec 20, 2011
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- MVIS US Listed Biotech 25 Index
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $375M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BBH Performance Chart
VanEck Vectors Biotech ETF (BBH) is up 0.1% since the beginning of the year. BBH is currently trading at $189 per share. Investors who bought $1,000 worth of BBH shares 5 years ago would now be looking at an investment worth $980.
Loading charts...
Returns By Period
VanEck Vectors Biotech ETF (BBH) has returned 0.06% so far this year and 24.78% over the past 12 months. Over the last ten years, BBH has returned 7.19% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
VanEck Vectors Biotech ETF
- 1D
- 0.92%
- 1M
- 2.50%
- YTD
- 0.06%
- 6M
- -1.66%
- 1Y
- 24.78%
- 3Y*
- 7.06%
- 5Y*
- -0.40%
- 10Y*
- 7.19%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BBH Monthly Returns History
Based on dividend-adjusted daily data since Nov 23, 1999, BBH's average daily return is +0.05%, while the average monthly return is +1.08%. At this rate, an investment would double in approximately 5.4 years.
Historically, 55% of months were positive and 45% were negative. The best month was Dec 1999 with a return of +38.9%, while the worst month was Mar 2001 at -22.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, BBH closed higher 52% of trading days. The best single day was Oct 13, 2008 with a return of +10.1%, while the worst single day was Apr 14, 2000 at -12.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.90% | 0.68% | -5.03% | -1.45% | 1.80% | 0.39% | 0.06% | ||||||
| 2025 | 5.27% | -0.41% | -4.41% | -3.01% | -2.79% | 3.33% | 5.71% | 1.94% | 0.31% | 9.33% | 9.19% | -3.83% | 21.18% |
| 2024 | 0.11% | -1.67% | 2.21% | -6.19% | 5.48% | 2.32% | 7.10% | 0.42% | -2.06% | -4.37% | -1.33% | -5.47% | -4.29% |
| 2023 | 5.01% | -6.83% | 3.71% | -1.46% | -3.19% | 0.92% | 3.03% | 1.76% | -4.82% | -7.29% | 5.07% | 9.45% | 3.94% |
| 2022 | -12.91% | -4.75% | 3.23% | -9.71% | 1.10% | -1.49% | 5.84% | -5.40% | -3.56% | 11.68% | 6.95% | -4.57% | -15.25% |
| 2021 | 10.37% | -4.42% | -1.99% | 7.60% | -2.45% | 9.52% | 2.64% | 4.41% | -6.47% | -1.31% | -1.86% | -3.10% | 11.81% |
Benchmark Metrics
VanEck Vectors Biotech ETF has an annualized alpha of 6.84%, beta of 0.87, and R2 of 0.37 versus S&P 500 Index. Calculated based on daily prices since November 23, 1999.
- This ETF participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (97.36%) than losses (80.21%) - typical of diversified or defensive assets.
- R2 of 0.37 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 6.84%
- Beta
- 0.87
- R²
- 0.37
- Upside Capture
- 97.36%
- Downside Capture
- 80.21%
Expense Ratio
BBH has an expense ratio of 0.35%, placing it in the medium range.
Return for Risk
Risk / Return Rank
BBH ranks 39 for risk / return — below 39% of ETFs on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for VanEck Vectors Biotech ETF (BBH) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBH | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | -0.83 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 2.36 | 2.78 | -0.42 |
| Martin ratioReturn relative to average drawdown | 5.69 | 12.44 | -6.74 |
Dividends
Dividend History
VanEck Vectors Biotech ETF provided a 0.51% dividend yield over the last twelve months, with an annual payout of $0.96 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.96 | $0.96 | $1.25 | $0.71 | $0.75 | $0.40 | $0.61 | $0.47 | $0.55 | $0.68 | $0.33 | $0.34 |
Dividend yield | 0.51% | 0.51% | 0.80% | 0.43% | 0.47% | 0.21% | 0.36% | 0.34% | 0.50% | 0.55% | 0.30% | 0.27% |
Monthly Dividends
The table displays the monthly dividend distributions for VanEck Vectors Biotech ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.96 | $0.96 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.25 | $1.25 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.71 | $0.71 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.75 | $0.75 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.40 | $0.40 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the VanEck Vectors Biotech ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the VanEck Vectors Biotech ETF was 72.70%, occurring on Jul 10, 2002. Recovery took 2207 trading sessions.
The current VanEck Vectors Biotech ETF drawdown is 12.14%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -72.70%Jul 2002 | 2y 4mo | 8y 9mo | 11y 1moMar 2000 - Apr 2011 |
Bear market2022 | -39.86%Jun 2022 | 10mo 7d | — | 4y 10moAug 2021 - now |
2016 bear market2016 | -33.76%Feb 2016 | 6mo 22d | 3y 10mo | 4y 5moJul 2015 - Dec 2019 |
2014 bear market2014 | -22.00%Apr 2014 | 1mo 15d | 4mo 17d | 6mo 2dFeb 2014 - Aug 2014 |
COVID crash2020 | -20.88%Mar 2020 | 21d | 1mo 2d | 1mo 23dFeb 2020 - Apr 2020 |
Drawdown Indicators
| BBH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.70% | -56.78% | -15.92% |
Max Drawdown (1Y)Largest decline over 1 year | -10.55% | -9.10% | -1.45% |
Max Drawdown (3Y)Largest decline over 3 years | -22.74% | -18.90% | -3.84% |
Max Drawdown (5Y)Largest decline over 5 years | -39.86% | -25.43% | -14.43% |
Max Drawdown (10Y)Largest decline over 10 years | -39.86% | -33.92% | -5.94% |
Current DrawdownCurrent decline from peak | -12.14% | -1.80% | -10.34% |
Average DrawdownAverage peak-to-trough decline | -20.73% | -10.71% | -10.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.36% | 2.03% | +2.33% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with BBH
Add VanEck Vectors Biotech ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BBH